Key facts
- It has raised $1.6M across 1 recorded rounds; the latest was Seed Round ($1.6M) in Jun 2022.
- Notable investors include Arben Ventures, One Mind, Lionheart Ventures, Fifth Street Ventures, Matthew McKibbin.
- Cognigenics has filed 1 Form D with the SEC, most recently Aug 2022 ($1.6M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cognigenics
Funding rounds
1 roundsAbout Cognigenics
Developer of mental healthcare drugs and therapies intended to transform mental health in the genetic age. The company specializes in cognitive neuro-engineering for the genetic engineering of desirable cognitive traits, such as mindfulness, relaxation, and mental acuity, enabling patients to offset cognitive deficits in people suffering from mental health issues such as stress, anxiety, and depression.
- Sector
- Healthcare
- HQ
- Eagle, ID, United States
- Founded
- 2019
- Employees
- 20
- Website
- cognigenics.io/
- Ownership
- Privately Held (backing)
Cognigenics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cognigenics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cognigenics in its N-PORT filings yet. We sweep new filings monthly.